GameStop Warrants Explained: What Shareholders Need to Know
GME gave shareholders warrants to buy stock at $32 until 2026. This could dilute owners but raises up to $1.9B for GME.
NOTRELOAD AI
ALTO-101 Receives FDA Fast Track for CIAS Treatment
Alto Neuroscience has received FDA Fast Track designation for ALTO-101, a potential new treatment for the cognitive difficulties—like poor memory and focus—that millions of schizophrenia patients experience, for which there are currently no approved options.
Big Boost for Ocular Therapeutix Stock and Drug Forecast
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.
Why One Analyst Thinks Apple's Stock Hopes Are Too High
Jefferies downgraded Apple stock because its price is "too high." It already assumes "overly bullish" success for the iPhone 17 and 18 Fold.
Red Cat and the $200M Drone 'Supercycle'
Needham initiated coverage of Red Cat, highlighting its strong position in the exploding drone market and the huge opportunity provided by the U.S. Army's SRR program.
Ovid Therapeutics Secures Major Funding & Announces Positive Drug Trial Results
Ovid Therapeutics secured up to $175 million in financing to fund its clinical pipeline into 2028. The company also reported positive Phase 1 results for OV329, a next-generation epilepsy drug candidate.